change in surface area and severity score was significantly improved in the exclusion diet compared to the normal diet at the end of 6 weeks (MD 5.50, 95% CI 0.19 to 10.81) and end of treatment (MD 6.10, 95% CI 0.06 to12.14).
Methodological difficulties have made it difficult to interpret these studies. Poor concealment of randomisation allocation, lack of blinding and high dropout rates without an intention-to-treat analysis indicates that these studies should be interpreted with great caution.
Authors' conclusions
There may be some benefit in using an egg-free diet in infants with suspected egg allergy who have positive specific IgE to eggs. Little evidence supports the use of various exclusion diets in unselected people with atopic eczema, but that may be because they were not allergic to those substances in the first place. Lack of any benefit may also be because the studies were too small and poorly reported. Future studies should be appropriately powered focusing on participants with a proven food allergy. In addition a distinction should be made between young children whose food allergies improve with time and older children/adults.
P L A I N L A N G U A G E S U M M A R Y

Dietary exclusions for improving established atopic eczema in adults and children
Atopic eczema is the most common inflammatory skin disease of childhood in developed countries. The cause of atopic eczema is probably due to a combination of genetic and environmental factors. Atopic eczema varies in severity, often from one hour to the next and the disease can be associated with complications such as bacterial and viral infections. There is a substantial economic cost not only to the family of the person with atopic eczema but also to health services. Although there is currently no cure for atopic eczema, a wide range of treatments are used to control the symptoms. One such approach is a dietary one, whereby certain foods such as cows' milk are excluded on the basis that they are thought to cause eczema to worsen. The reason for undertaking this review is because the effectiveness of removing various foods from the diet in the short term management of atopic eczema is unclear.
The general quality of the studies was poor. The main findings of the review suggest that there is some evidence from one study for the use of an egg-free diet in infants with a suspected egg allergy who have positive specific IgE antibodies to eggs in their blood. Other studies that compared a dietary exclusion with ordinary diets did not test the people taking part to see if they were allergic to the foods concerned. There appears to be little benefit in eliminating cows milk from the diet or using an elemental (liquid diet containing only amino acids, carbohydrates, fat, minerals and vitamins) or 'few foods diet' for improving atopic eczema in people who have not undergone any form of testing.
Three of the studies used soya based substitute which itself can be allergenic to people with atopic eczema.
Adhering to elimination diets is difficult. The studies were performed in different populations with only one study describing the severity of the atopic eczema. The clinical relevance of changes in severity scores obtained in many studies is unknown.
B A C K G R O U N D Description of the condition Disease definition
Atopic eczema (AE) is a non-infective chronic inflammatory skin disease characterised by an itchy red rash. The terms 'atopic eczema' and 'atopic dermatitis' are used synonymously. "Atopy" refers to a form of allergy in which there is a heritable tendency to develop "IgE" hypersensitivity reactions. However up to 40% of children with atopic eczema are not atopic, when defined according to allergy tests such as skin prick tests (Bohme 2001). Others have found that up to two thirds of people with atopic dermatitis are not atopic (Flohr 2004) , implying that continued use of the term 'atopic dermatitis' is problematic. The new nomenclature is based on the mechanisms that initiate and mediate allergic reactions. The term 'eczema' is proposed to replace the provisional term 'atopic eczema/dermatitis syndrome' (AEDS). What is generally known as 'atopic eczema/dermatitis' is probably not one single disease but rather an aggregation of several diseases with certain characteristics in common. The term 'atopy' cannot be used until an IgE sensitisation has been documented by IgE antibodies in the blood of a person or by a positive skin prick test to common environmental allergens such as pollen, house dust mite, cow's milk or egg. If this is done then the term 'eczema' can be split into 'atopic eczema' and 'non-atopic eczema'. Whilst recognising the logic of the new nomenclature, most health care workers still think of atopic eczema as the clinical syndrome of an itchy inflammatory skin condition with a tendency to settle in the skin creases without doing any further investigations to find out if such individuals are atopic. For the purpose of this review therefore, we will use the term 'atopic eczema' throughout for ease of communication, knowing that in many cases, testing for atopy in such individuals has not been carried out. Since it is possible that individuals who are allergic to a particular substance are more likely to respond to a diet that excludes that substance than people who do not react to such tests, we will make it clear which studies have undertaken such allergy tests to further define the study populations in this review.
Epidemiology and causes
Atopic eczema is the most common inflammatory skin disease of childhood in developed countries, affecting 15 to 20% of children in the UK at any one time (Hoare 2000). Two-thirds of people with the disease have a family history of atopic eczema, asthma or hay fever. The cumulative prevalence of atopic dermatitis varies from 20% in Northern Europe and the USA to 5% in the SouthEastern Mediterranean (Thestrup 2002) . Prevalence data for the symptoms of atopic eczema were collected in the global ISAAC study (International Study of Asthma and Allergies in Childhood). The results of this study suggest that atopic eczema is a worldwide problem affecting 15 to 20% of children (Williams 1999) . Of those children with atopic eczema, only 2% under the age of 5 years have severe disease and 84% have mild disease (Emerson 1998) . Two per cent of adults have atopic eczema and many of these have a more chronic and severe form (Charman 2002). Atopic eczema is often associated with other atopic diseases e.g. asthma and rhinitis (Beck 2000). The incidence of common allergic disease has increased in the past 30 years (Fendrick 2001 ) and the increase in prevalence of atopic disease in the past 3 decades appears to be a real phenomenon and has been observed in countries as far apart as Japan, USA, Finland and Africa (Williams 1992). The cause of eczema is not well understood and probably is due to a combination of genetic and environmental factors 
Clinical features
Atopic eczema may be acute (short and severe) with redness, scaling, oozing and vesicles, or it may be chronic (long-term) with skin thickening, altered pigmentation and exaggerated surface markings. The condition affects mainly the creases of the elbows and knees, and the face and neck, although it can affect any part of the body. The severity of eczema is variable, ranging from localised mild scaling to generalised involvement of the whole body with redness, oozing and secondary infection. Itching is the predominant symptom which can induce a vicious cycle of scratching, leading to skin damage, which in turn leads to more itching -the so called "itch scratch itch" cycle. There is a tendency to a dry sensitive skin even in those who have 'grown out' of the disease. This is thought to be due to a defect in the lipid barrier of the epidermis. In adulthood, the skin (especially of the hands) may be prone to inflammation in the presence of environmental irritants such as soaps (Archer 2000).
Natural history
Atopic eczema usually starts within the first 6 months of life, and by 1 year, 60% of those likely to develop it will have done so. Remission occurs by the age of 15 years, in 60 to 70% of cases, although some relapse later. In the more severely affected child, development and puberty may be delayed (Baum 2002). Many children with eczema go on to develop asthma and hay fever, which might also be triggered by food allergy (Ricci 2006)
Impact
Atopic eczema varies in severity, often from one hour to the next. Severity can be measured in a number of ways. A systematic review of named outcome scales for atopic eczema found that of the 13 named scales in current use, only one (Severity Scoring of Atopic Dermatitis, SCORAD) had been fully tested for validity, repeatability and responsiveness (Charman 2000). Itching and scratching can adversely affect quality of life through chronic sleep disturbance. This may have an impact on family life. The disease can be associated with complications such as bacterial and viral infections (McHenry 1995) . The unsightly appearance of the skin and the need to apply greasy ointments can limit a child's inclination to participate in social and sporting activities and thus affect their confidence. Adults with atopic eczema often have low self-esteem and relationships can be difficult to initiate and sustain. Everyday tasks such as housework, gardening, childcare and food preparation present problems when the skin on the hands is cracked.
Promotion at work may be blocked for people who do not 'look good'. There is a substantial economic cost not only to the family of the person with atopic eczema (Kemp 2003) but also to the health services of the country as a whole (Herd 1996; Verboom 2002) . Direct costs to the family are encountered when purchasing treatments, special clothing and bedding; indirect costs are experienced from lost working days when parents are looking after a sick child. The wider economic implications lie in the costs of health professionals, the lost opportunities of parents of sick children who do not have the option of seeking employment and the child who, as a result of missing schooling, has limited employment prospects (Su 1997).
Description of the intervention
There is currently no cure for atopic eczema. However a wide range of treatments are employed which aim to control the symptoms 
How the intervention might work Diet and atopic eczema
Food hypersensitivity may be the first stage in the development of 'allergic diseases' such as atopic eczema (Chandra 2002). Food allergy may be an important factor in up to 20% of children with atopic eczema under 4 years (Oranje 2000). The incidence of food allergy is highest around the age of six to nine months. Many clinicians have found that elimination of specific foods found by food challenge to elicit symptoms can lead to significant improvement in eczematous symptoms (Sampson 2003) . Challenges in people with food allergies can lead to eczematous lesions and infiltration of allergic inflammatory cells and animal studies have suggested that eczema may be caused by food allergies (Li 2001). However, many food reactions in people with atopic eczema may not necessarily be mediated through immune reactions (David 2000). As sensitisation to food early in life may be a predisposing factor (Baena-Cagnani 2001) it is important to investigate whether the elimination of dietary triggers could help to alleviate the symptoms of atopic eczema. The role of dietary factors in atopic eczema either as a cause or as a treatment, through the use of exclusion diets, remains unclear (Oranje 2000). Many trialists advocate double blind placebo controlled food challenges to establish whether a child has a true food allergy (Sampson 1992). There is a vast amount of literature claiming that dietary elimination causes improvement of atopic eczema in some cases. However, much of the evidence fails to withstand close scrutiny (David  2000) . There are three main types of dietary exclusion (David 2000): (1) the simple elimination of cow's milk protein and egg; (2) 'the few foods' diet (a diet in which all but a handful of foods is excluded) (David 1993). One problem with the 'few foods diet' is poor adherence because the diet is so restrictive (Hathaway 1983; David 1989); (3) the 'elemental' diet, more accurately described as a non-macromolecular diet since ordinary foodstuffs are all avoided, and the participant receives a liquid diet which contains amino acids, carbohydrate, fat, minerals and vitamins. The palatability of the elemental formula is poor. Many people, with or without their doctor's or dietician's help, experiment by excluding a particular food suspected of causing a reaction for a variable time. Most investigators would base elimination diets upon proven food allergies, either by challenge or serum food-specific IgE antibodies exceeding specific diagnostic decision points (Sampson 2001). The advantage of dietary interventions is that they may address one of the primary causes, as opposed to merely suppressing the symptoms, although there can be serious consequences to any dietary manipulation that leaves the individual deficient in calories, protein or minerals such as calcium. (David 1984; Devlin 1989) . Avoidance of multiple foods is potentially hazardous and requires continued paediatric and dietary supervision (David 1984) . The role of food is much debated in atopic eczema, but the allergenic relevance of some proteins seems to be important only in a small number of people, especially in the first years of life (Svejgaard 1985) .
Why it is important to do this review
The rationale for a review on dietary exclusions for established atopic eczema is:
• currently there is no cure for atopic eczema;
• diets excluding foods, such as cow's milk, are commonly tried (Graham-Brown 2000);
• the place for dietary elimination in the short-term management of atopic eczema is unclear (Smethurst 2002);
• some have claimed that there is no evidence of long-term benefit from dietary elimination (David 2000).
O B J E C T I V E S
To assess the effects of general dietary avoidance practices for the treatment of established atopic eczema.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) of dietary exclusion for the treatment of established atopic eczema/dermatitis. We excluded double blind placebo controlled food challenges conducted in isolation, since these are not therapeutic trials but diagnostic or provocation tests. Comparisons considered were active exclusion diet vs control or a comparison of two active diets.
Types of participants
We included participants who had atopic eczema diagnosed by a doctor. In the National Health Service Technology Assessment (HTA) systematic review of treatments for atopic eczema (Hoare 2000), specific terms were used to identify trial participants as listed in Table 1 . The list classifies conditions into 'definite', 'possible' and 'not' atopic eczema and we have used this list as a guide. We excluded those studies using terms in the 'not atopic eczema' category such as 'allergic contact eczema' . We found some studies using terms in the 'possible atopic eczema' category, such as 'childhood eczema' . One or more authors scrutinised these and we included them if the description of the participants clearly indicated atopic eczema (i.e. itching and flexural involvement).
Types of interventions
We included studies with exclusions of any type of food, either singly or in combination with other foods.
Types of outcome measures
Primary outcomes (a) Short-term (within six weeks). Changes in parent-rated or mother-rated symptoms of atopic eczema such as itching (pruritus) or sleep loss. (b) Degree of long-term (over six months) control, such as reduction in number of flares or reduced need for other treatments.
Secondary outcomes
(a) Global severity as rated by the participants or their physician. Where the outcome was not available then the following was used: (b) Global changes in composite rating scales using a published named scale Where this was not possible, we used: (c) The trial author's modification of existing scales or new scales Also: (d) Quality of life (Finlay 1996; Chren 1997) (e) Palatability of the diet (f ) Adverse events including long term consequences on growth.
Tertiary outcome measures
Changes in individual signs of atopic eczema as assessed by a physician e.g. erythema (redness), purulence (pus formation), excoriation (scratch marks), xerosis (skin dryness), lichenification (thickening of the skin), fissuring (cracks), exudation (weeping serum from the skin surface), pustules (pus spots), papules (spots that protrude from the skin surface), vesicles (clear fluid or 'water blisters' in the skin), crusts (dried serum on skin surface), infiltration/ oedema (swelling of the skin), induration (a thickened feel to the skin). References from published studies were checked for further trials.
Search methods for identification of studies
Unpublished literature
Where possible unpublished, on-going trials were obtained via correspondence with the trial authors. The metaRegister of Controlled Trials www.controlled-trials.com, www.clinicaltrials.gov and www.nottingham.ac.uk/ongoingskintrials were searched in March 2006 for ongoing trials using the terms atopic eczema, atopic dermatitis.
Pharmaceutical companies
Pharmaceutical companies were contacted, where appropriate, for reviews or unpublished trials.
Language
No language restrictions were imposed and translations were obtained where possible.
Data collection and analysis
Selection of studies
One author (FD) ran the searches, then two authors (FB-H and FD) checked the titles and abstracts for relevance. Three authors (FB-H, HW and FD) then independently assessed the full text of the identified RCTs and decided whether they fitted our inclusion criteria. Where there were any disagreements they were resolved by discussion between the authors. Where there were missing data from the trials we contacted the trial authors.
Data extraction and management
Two authors (FB-H and FD) independently extracted the data using a data extraction form for consistency. We resolved any discrepancies by discussion. One author (FB-H) entered the data.
Assessment of risk of bias in included studies
Our quality assessment included an evaluation of the following components for each included study, since there is some evidence that these are associated with biased estimates of treatment effect (Juni 2001): (a) the method of generation of the randomisation sequence; (b) the method of allocation concealment -it was considered 'adequate' if the assignment could not be foreseen; (c) who was blinded/not blinded (participants, clinicians, outcome assessors); (d) how many participants were lost to follow up in each arm, and whether participants were analysed in the groups to which they were originally randomised (intention to treat). In addition, the quality assessment also included: (e) degree of certainty that the participants had atopic eczema; (f ) baseline comparability of the participants for age, sex and eczema severity; (g) assessment of compliance with treatment. We recorded the information in a table of quality criteria Table 2 and a description of the quality of each study is given based on a summary of these components.
Measures of treatment effect
For studies with a similar type of intervention, we performed a meta-analysis, to calculate a weighted treatment effect across trials, using a random effects model. We have expressed the results as risk ratio (RR) and 95% confidence intervals (CI) for dichotomous outcomes and mean differences (MD and 95% CI) for continuous outcomes. The results are also expressed as number needed to treat (NNT) where appropriate, for a range of plausible control event rates. Where it has not been possible to perform a meta-analysis the data have been summarised for each trial.
Unit of analysis issues
Where paired data were available for cross-over studies we calculated the conditional odds ratio with 95% CI using the methodology as described by Elbourne 2003. If paired data were not available then data, where available, were taken from the first phase of the cross-over study and if appropriate then the first phase was treated as a parallel study. Cross-over studies are not ideal for dietary exclusion studies since carry-over effects may invalidate data in the second period. Non-randomised controlled studies are listed but not discussed further. Studies relating to adverse effects are described qualitatively.
Assessment of heterogeneity
Heterogeneity was assessed using I 2 .
Data synthesis
Where participant-rated symptoms were reported on categorical Likert scales (e.g. no improvement, mild improvement, good improvement, excellent), we dichotomised the data by defining a cutoff at 'good to excellent improvement'. Where data were reported on continuous scales (e.g. number of days sleep loss), we regarded a 20% reduction/improvement compared to control as being clinically significant. Not enough studies used SCORAD for us to be able to split eczema severity into mild, moderate and severe where mild is 0 to 15, moderate is 15 to 40 and severe is >40. Where data on existing medication usage were included, we have attempted to see whether this has increased differentially in one of the treatment arms as the main dietary intervention has proceeded.
Subgroup analysis and investigation of heterogeneity
Where substantial heterogeneity (I 2 >50%) existed between studies for the primary outcome, we have explored the reasons for heterogeneity, such as disease severity, whether food allergy was confirmed by a prior provocation/serum test, dosage etc. In future updates of this systematic review, we will perform further subgroup analysis, where there is sufficient information to do so. This will be done in those studies of infants (under one year old) and children (aged 1 to 16 years) versus adults and for those participants who had a positive food challenge prior to entry into the trial.
Sensitivity analysis
We may also conduct sensitivity analyses to examine the effects of excluding poor quality studies, defined as those studies that do not clearly report the randomisation process, blinding and no intention to treat.
Other
Where there was uncertainty, we contacted trial authors for clarification.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies.
Results of the search
We identified 12 RCTs of which 9 were included.
Included studies
Only two studies were considered sufficiently similar to pool ( Isolauri 1995; Niggemann 2001). The studies fell into three main categories -see 'Characteristics of included studies'. 1. Egg and cow's milk exclusion diets 2. Few foods diet 3. Elemental diet
Egg and cows milk exclusion diets
Six RCTs, three of which were cross-over studies (Atherton 1978; Cant 1986; Neild 1986) and three were parallel studies (Isolauri 1995; Lever 1998; Niggemann 2001)
• Egg and cow's milk exclusion diet (with soya substitute) vs egg and cows' milk (Atherton 1978)
• Egg and cow's milk exclusion diet (with soya substitute) vs egg and cows' milk in breastfeeding mothers (Cant 1986)
• Whey hydrolysate vs amino acid derived formula (Isolauri 1995)
• Egg and cow's milk exclusion diet (with soya substitute) vs normal diet (Neild 1986)
• General advice on care of atopic eczema and specific advise about egg exclusion diet vs general advise from dietician only (Lever 1998)
• Amino-acid-based (AA)formula vs extensively hydrolysed whey formula (Niggemann 2001)
Few foods diet
One RCT, a parallel study
• Few foods diet plus whey hydrolysate vs few foods diet plus casein hydrolysate versus usual diet (Mabin 1995)
Elemental diet
Two RCTs, one was a cross-over study (Leung 2004 ) and one was a parallel study (Munkvad 1984) • Elemental diet vs blended diluted diet of foodstuffs consumed by hospital inpatients (Munkvad 1984).
• Hypoallergenic, milk free lactose and sucrose-free, complete elemental formula with free amino-acid (AA) vs participants pre existing formula (Leung 2004).
Excluded studies
We excluded three studies (see Characteristics of excluded studies) as they did not fit our inclusion criteria for 'types of intervention' (Majamaa 1997; Isolauri 2000; Kirjavainen 2003). 
Risk of bias in included studies
Allocation
In seven of the studies in this review the method of randomisation was not described at all or was unclear. Two of the studies used a random number table (Cant 1986; Mabin 1995). In none of the studies did the trial authors clearly demonstrate adequate concealment of allocation.
Blinding
Only one study blinded participants, clinicians and outcome assessors ( 
Incomplete outcome data
Analysis should be performed according to the intention-to-treat principle, thus avoiding bias (Sackett 1979; May 1981; Altman 1991). However in many of the studies analysis of outcome was carried out only in those participants who completed the study. Only one study analysed by intention-to-treat (Isolauri 1995). For one study (Niggemann 2001) it was impossible to know if the analysis was intention-to-treat as no results tables were given or numbers mentioned in the text. All but two studies stated numbers and reasons for participants lost to follow up. One study (Isolauri 1995) had no loss to follow up, possibly due to the highly selected population.
Other potential sources of bias Degree of certainty that participants had (atopic eczema) AE
The certainty of AE was clear for four studies (Munkvad 1984; Cant 1986; Mabin 1995; Niggemann 2001) that used criteria by Hanifin or Yates. One study stated that they included clinically typical AE (Atherton 1978) and all the other studies did not state how they diagnosed AE.
Baseline comparability of the participants for age, sex, and eczema severity
In one study the diet group had slightly more extensive and more severe involvement than the controls (Lever 1998). Two studies clearly stated that there were no differences in baseline comparability (Mabin 1995; Niggemann 2001). For all other studies it was not clear if there was baseline comparability of the participants.
Assessment of compliance
Compliance was clear in only three studies (Munkvad 1984; Neild 1986; Mabin 1995).
Severity of AE
Severity of AE was clear for only one study (Munkvad 1984) .
Effects of interventions
The secondary outcome measures: (a) Global severity as rated by the participants or their physician, (b) Global changes in composite rating scales using a published named scale and (c) The trial author's modification of existing scales or new scales, have not been listed as we originally planned. This is because it was not possible to exactly match these outcomes with what we actually found. Instead we described the disease activity as we found it in each of the studies.
Egg and cows milk exclusion diets
Six RCTs of which three were cross-over studies and three were parallel studies.
Cross-over studies
All three studies (Atherton 1978; Cant 1986; Neild 1986) were conducted in different populations. One study was conducted in children of 2 to 8 yrs (Atherton 1978), one in breastfeeding mothers and babies (Cant 1986), and one in children and adults 1 to 23 yrs (Neild 1986). Three studies used soya milk as a control food which in itself can be allergenic in AE. All studies measured severity of AE in different ways. For these reasons the studies were not considered suitable to pool.
Atherton 1978
The first cross-over study (Atherton 1978) of 36 unselected children (2 to 8 yrs) compared a soya based preparation (egg and milk exclusion) vs dried egg and cows' milk over three four-week periods. Main outcomes were eczema activity and area (using unpublished scale) pruritus, sleeplessness and antihistamine usage.
(1) Primary outcome measures (a) Short-term (within six weeks). Changes in participant-rated or mother-rated symptoms of atopic eczema such as itching (pruritus) or sleep loss. Pruritus improved during the trial diet compared to the control diet. A small non significant order effect (i.e. improvements greater at the end of the first versus the second period whatever the diet content) with pruritus scores being lower during the first diet period than during the second diet period.
Sleeplessness was significantly lower during the trial period as compared to control period (p < 0.05), and the order effect was greater than the treatment effect.
(b) Reduced need for other treatments. Significantly fewer antihistamine tablets were used in the trial diet period.
(2) Secondary outcome measures
Eczema area and activity (using unpublished composite score assessed by physician). Eczema activity scores (major improvement +2; minor improvement +1; no change 0; minor deterioration -1; major deterioration -2) which recorded change of eczema activity during each diet period showed significantly more improvement after the trial diet than after control diet (p < 0.001). A significant order effect was apparent but this was smaller than the treatment effect. Area scores (the body surface was divided into 20 separate zones, each of which was recorded as affected or unaffected; this gave an area score of up to 20) improved significantly during the trial period (p < 0.005). A significant order effect was apparent but this was smaller than the treatment effect. From the paper we were able to calculate the difference between the proportions of children whose activity score improved and those whose score did not improve, based on paired observations from the same individual. Eczema activity scores improved significantly for children on the exclusion diet as compared to the control diet (Conditional OR 10.52, 95% CI 2.27 to 48.80; Analysis 1.1). The second cross-over study (Cant 1986) in 19 unselected breast feeding mothers and babies (6 weeks to 9 months of age) compared a soya based preparation (egg and milk exclusion) vs egg and milk diet over three four-week periods. Due to insufficient data we were unable to calculate the conditional odds ratio for this study or analyse the first period only as from a parallel group trial.
1) Primary outcome measures
(a) Short-term (within six weeks). Changes in parent-rated or mother-rated symptoms of atopic eczema such as itching (pruritus) or sleep loss. No data (b) Reduced need for other treatments.
There was no significant difference in the amount of steroid cream applied in each period.
(2) Secondary outcome measures
Two continuous scale eczema severity scores: area (number of involved body areas from 0 to 20) and activity (severity within each areas on 0 to 3 scale x number of involved areas) Mean eczema severity scores decreased during the trial and at the end of the study when the mothers returned to a normal diet for four weeks. The scores were significantly lower than they had been at the beginning (p < 0.01). There was a marked period effect in that children of mothers on the normal diet in the third period continued to improve. No data given (f ) Adverse events Two mothers withdrew -one mother vomited after soya milk and another mother's baby developed eczema and bloody diarrhoea within 24 hours of her taking the diet containing cows milk and egg. One infant developed watery stools with mucus when his mother took the substitute containing cow's milk and egg. Neild 1986 A third cross-over study (Neild 1986 ) in 53 unselected children and adults (1 to 23 yrs) compared a cow's milk exclusion diet (soya milk) vs milk containing egg and cows milk for 6 weeks. Due to insufficient data we were unable to calculate the conditional odds ratio for this study or analyse the first period only as from a parallel group trial.
1) Primary outcome measures
(a) Short-term (within six weeks). Changes in participant-rated or mother-rated symptoms of atopic eczema such as itching (pruritus) or sleep loss. The trial authors reported no significant difference in total itch score at end of trial diet compared to end of normal diet (b) Reduced need for other treatments. More topical steroids were used while on the trial diet .
(2) Secondary outcome measures
The body surface was divided into 20 zones using the method of Atherton 1978, and the presence of acute eczema (erythema and vesiculation) and chronic eczema (lichenification and prurigo papules) was noted, both on a scale from 0 to 3.
The trial authors reported that no statistically significant difference was shown between the scores at the end of the trial diet compared with those at the end of the normal diet or between the scores at the end of the trial diet compared with those at the end of the control diet. At the end of the study 25% (10/40) of adults and children appeared to have improved on the trial diet and had lower area scores and itch scores than on the normal diet or on the control. Of those who responded, five were in the youngest age group and two were non-Caucasians. More responders had the trial diet first than the group as a whole. The first study (Isolauri 1995) was in a population of 45 infants (6 to 7 months) with a positive reaction to cow's milk challenge that compared eHF (extensively hydrolysed whey formula) vs AA (amino acid formula) containing no peptides for 9 months.
The second study (Niggemann 2001) in 73 infants (1 to 10 months) with a cows' milk allergy/intolerance (proved by a double-blind, placebo controlled food challenge), compared an AA formula vs eHF for 6 months.
1) Primary outcome measures
(a) Short-term (within six weeks). Changes in participant-rated or mother-rated symptoms of atopic eczema such as itching (pruritus) or sleep loss. No data for either study (b) Degree of long-term (over six months) control, such as reduction in number of flares or reduced need for other treatments. No data for either study (2) Secondary outcome measures There was no difference seen in eczema severity (using the SCO-RAD index) at 2 to 3 months (pooled analysis, 2 studies, MD 0.00, 95% CI -4.87 to 4.87; Analysis 2.1) or 6 to 8 months (pooled analysis, 2 studies, MD 1.06, 95% CI -1.67 to 3.80; Analysis 2.2). No data for either study Lever 1998 The third study (Lever 1998) in 62 infants (11 to 17 months ) with sensitivity to eggs compared an egg exclusion diet as advised by a dietician (in the diet group) vs general advice from a dietician (in the control group) for 4 weeks.
(a) Short-term (within six weeks). Changes in participant-rated or mother-rated symptoms of atopic eczema such as itching (pruritus) or sleep loss. No data available (b) Degree of long-term (over six months) control, such as reduction in number of flares or reduced need for other treatments. No data available
(2) Secondary outcome measures
Area affected (% of total skin area) using 'rule of nine' Severity score in arbitary units which assesses six clinical features (extent, erythema, oedema/papulation, oozing/crusts, dryness, lichenification) on a scale of 0 to 3 units at 16 body sites. At the end of the study 51% of the children had a significant improvement in body surface area with the exclusion diet compared to normal diet (RR 1.51, 95% CI 1.07 to 2.11; Analysis 3.1). Change in surface area and severity score (6 clinical features on a scale of 0 to 3 units at 16 body sites) was significantly improved in the egg exclusion diet group as compared to the normal diet at the end of 6 weeks and end of treatment (MD 5.50, 95% CI 0.19 to 10.81; Analysis 3.2 and MD 6.10, 95% CI 0.06 to 12.14; Analysis 3. 
Few foods diet
One RCT, which was a parallel study (Mabin 1995), randomised 85 children (0.3 to 13.3 yrs), with atopic eczema affecting more than 12% of the body, to one of three groups: i) few foods diet (eliminating all but five to eight foods) plus whey; ii) few foods diet plus casein hydrolysate; or iii) usual diet.
1) Primary outcome measures
(a) Short-term (within six weeks). Changes in participant-rated or mother-rated symptoms of atopic eczema such as itching (pruritus) or sleep loss.
There was no significant difference in daytime itch when comparing: few foods diet with casein compared to normal diet (MD -0.6, 95% CI -1.46 to 0.26; Analysis 5.1); few foods diet with whey compared to few foods with casein (MD 0.5, 95% CI -1.69 to 2.69; Analysis 6.1); few foods with whey vs normal diet (MD -0.10, 95% CI -2.22 to 2.02; Analysis 4.1). There were no significant differences in sleep disturbances at 6 weeks for: few foods with whey vs normal diet (MD -0.30, 95% CI -2.51 to 1.91; Analysis 4.2); few foods with casein vs normal diet (MD -0.10, 95% CI -0.90 to 0.70; Analysis 5.2); few foods with whey vs few foods with casein (MD -0.20, 95% CI -2.50 to 2.10; Analysis 6.2). 
Elemental diet
Two RCTs, one was a cross-over study (Leung 2004 ) and one was a parallel study ( Munkvad 1984) .
Munkvad 1984
The first study (Munkvad 1984) randomised 33 adults (16 to 25 yrs) to either an elemental diet (amino acids, essential fatty acids, glucose, trace elements, sorbic acid and vitamins) or a blended diluted diet of foodstuffs consumed by hospital inpatients. Participants remained in hospital for the three week study.
1) Primary outcome measures
(a) Short-term (within six weeks). Changes in participant-rated or mother-rated symptoms of atopic eczema such as itching (pruritus) or sleep loss. Short-term (within six weeks). There was no significant difference between the two groups for the combined outcome of pruritus, sleeplessness and antihistamine usage (RR 1.69, 95% CI 0.2 to 13.93; Analysis 7.2) (2) Secondary outcome measures There was no significant difference at three weeks between the two groups for improvement of intensity and extension of the eczema (RR 0.7, 95% CI, 0.25 to 1.97; Analysis 7.1) measured by a major activity score. A major activity score of > 100 was the criterion for a positive response to treatment. However there was a non significant trend in favour of the normal diet. d) Quality of life No data given (e) Palatability of the diet Six withdrew due to a dislike of the diet (f ) Adverse events including long term consequences on growth No data given Leung 2004 A cross-over study (Leung 2004) in 15 children (< 3 yrs) compared hypoallergenic, milk-free, complete elemental formula with free AA (trial milk) vs participants pre existing formula (placebo) for 6 weeks.
No data given 
D I S C U S S I O N
Summary of main results
We found some evidence to support the use of an egg-free diet in infants with a suspected egg allergy who have a positive specific IgE to eggs in their blood. This perhaps highlights the importance of allergy testing beforehand. Only 2 of the other 11 included studies tested for food allergy (Isolauri 1995; Niggemann 2001), but those studies dealt with comparisons of 2 different forms of exclusion diets rather than a comparison of an exclusion diet versus normal diet, and have therefore not contributed to the question of whether any form of exclusion diet is helpful in such people. The other included studies of unselected people with atopic eczema did not find any evidence of benefit for exclusion diets. It is useful to know that exclusion diets given to unselected people with atopic eczema are not likely to be helpful, as benefit from dietary exclusions could be due to non-allergic mechanisms. Not showing any benefit from such dietary exclusions in unselected people does not mean they are not helpful in people with proven allergy to that particular food. Three of the RCTs used potentially allergenic soya based milk substitute which itself can be allergenic in atopic eczema. Adverse events for people on exclusion diets included gastrointestinal symptoms followed by exacerbation of eczema or just exacerbation of eczema.
Overall completeness and applicability of evidence
This systematic review has only addressed dietary exclusion and has not addressed dietary supplements including probiotics which are the subject of another review. The clinical importance of changes in severity scores obtained in many studies is unknown. Dropout rates are particularly high for elimination diets and those containing hydrolysate milk substitutes and this will always remain a problem. Overall interpretation of the above studies was difficult due to the poor methodological quality of the studies.
Quality of the evidence
Nine poor quality studies were included in the review involving 421 participants: 6 egg and cow's milk exclusion diets; 1 was a few foods diet; 2 were elemental diets. Of the egg and cow's milk exclusion diets, three studies used soya based milk substitute which itself can be allergenic in atopic eczema. Three small cross-over studies studied various populations ranging from infants to adults. Only two studies followed participants for more than six months. Long-term outcomes and consequences of an egg and milk free diet were not discussed by any of the studies. One study in unselected breast feeding mothers and babies found an improvement in their babies eczema during the exclusion period and when they went back to their normal diethowever possible improvement may well have been spontaneous. One small study in unselected children found a significant improvement in eczema severity during the trials period when an egg and milk exclusion diet was compared to an egg and milk diet, however just under half of the participants were not included in the final analysis. One study in infants (11 to 17 months) with sensitivity to eggs found a significant improvement in body surface area with the exclusion diet compared to normal diet. One study of the few foods diet found no significant change in body surface area, skin severity score, sleep disturbances in children when few foods diet plus whey compared to few foods diet plus casein hydrolysate or usual diet. Two elemental diet studies were unable to find any significant difference in eczema severity when an elemental diet was compared to a normal hospital diet in adults or when an elemental diet was compared to a pre existing formula in children. Elemental diets are difficult since they are unpalatable for many and required hospitalisation and dietetic input.
Potential biases in the review process
Very few studies have been found and in seven of the included studies the method of randomisation was not described at all or was unclear.
Agreements and disagreements with other studies or reviews
The results of this review are in agreement with a previous HTA review (Hoare 2000).
A U T H O R S ' C O N C L U S I O N S
Implications for practice
Elimination diets can be difficult to follow. The studies were performed in different populations with only one study giving results on the severity of atopic eczema. The clinical importance of small changes in severity scores obtained in many studies is unknown. Although diets excluding foods such as cows' milk are commonly tried there is little evidence for benefit in their use in unselected people with atopic eczema. That does not mean to say that they could not be beneficial in people with proven cows' milk allergy, but such studies have not been done yet. There may be some benefit in the use of an egg-free diet in infants with a suspected egg allergy who have a positive specific IgE to eggs in their blood. There does not appear to be any benefit in the use of elemental or few foods diet in unselected people with atopic eczema.
Implications for research
Future studies should be big enough to answer the questions posed, and well reported according to CONSORT guidance (Moher 2001). Common sense suggests that studies of food allergy exclusions should be done on people with a history of suggested food allergy, confirmed by appropriate allergy testing or challenge tests. A distinction should be made between young children, older children and adults, because food allergy in children tends to improve in time. Disease severity should be measured using valid instruments and include quality of life assessments and patient-centred outcomes that are easy to interpret clinically. Where possible, longterm outcomes (greater than six months) should also be recorded in such studies.
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The editorial base would like to thank the following people who were the external referees for this review: Hugh Sampson and Peter Arkwright (content experts) and Shirley Manknell and Carol O'Brien (consumers). Interventions Three four week periods. During first and third period participants were placed on an egg and milk elimination diet and they were randomlly allocated to one of two milk substitutes. During 1 period the participants were given a dried soya-based pepraration (trial period), during the other they were given a preparation containing a mixture of dried egg and cows' milk (control period). During the middle period participants resumed their normal diet, to minimise any carry-over effect Outcomes Eczema area and activity (using unpublished composite score assessed by physician), degree of adherence to diet, skin prick tests, pruritus, sleeplessness and antihistamine usage Notes PP.16 loss to FU(44%). Nine excluded due to dietary lapses, seven withdrew voluntarily (four during or after control period, three during or after trial period), . Marked order effect i.e. improvements greater at end of first vs second period whatever the diet content. Soya milk (which itself can be allergenic in atopic eczema) used as 'control' food Interventions Following a four week run in patients randomised to either Hypoallergenic, milk-free, lactose and sucrosefree, complete elemental formula with free AA (Neocate) or placebo (patients pre existing formulae) for six weeks. This was followed by a wash out period of six weeks and then crossed over to the other intervention for six weeks Outcomes AD severity was assessed using SCORAD before and after each phase Notes PP Four drop outs: two drank less than daily milk requirement, one refused to drink Neocate and one was discontinued due to too mild AD Interventions Elemental diet (amino acids, essential fatty acids, glucose, trace elements, sorbic acid and vitamins) vs blended diluted diet of foodstuffs consumed by hospital inpatients. Diet for three weeks Outcomes Various unpublished extent and intensity signs scored. A score between -3 and +3 was given to the degree of change for each of the clinical symptoms (erythema, infiltration and size of area involved). In addition photographs before and after, patient itch and sleep, and various serum markers of inflammation. In evaluation the mean value of these four figures was multiplied by 100 and named 'major activity score'. A 'major activity' score of >100 was defined as the criterion for a positive response to treatment Notes PP. Eight lost to FU-(24%) mostly due to dislike of diet. Small study of intervention that is unpalatable, impractical and requires hospitalisation and dietetic input
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Atherton 1978
Methods
Risk of bias
Item
Authors' judgement Description
Risk of bias
Item
Risk of bias
Item
Authors' judgement Description
Allocation concealment? Unclear B -Unclear Heterogeneity: Tau 2 = 0.0; Chi 2 = 0.0, df = 1 (P = 1.00); I 2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0) 
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